drugset / Trial / NCT00572182
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Phase 1
Terminated
33 enrolled
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with recurrent or refractory CNS cancer.
Timeline
- Start
- 2008-07
- Primary completion
- 2011-02
- Completion
- 2011-02
Outcome
Outcome not reported
Stopped (Enrollment): “This Phase I study was permanently closed to patient accrual on February 23, 2011, due to the discontinuation of support from MERCK.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-0752 | Small molecule | 150 mg/m2 | Oral |
| Subject | MK-0752 | Small molecule | 200 mg/m2 | Oral |
| Subject | MK-0752 | Small molecule | 260 mg/m2 | Oral |
| Subject | MK-0752 | Small molecule | 325 mg/m2 | Oral |
| Subject | MK-0752 | Small molecule | 800 mg/m2 | Oral |
| Subject | MK-0752 | Small molecule | 1000 mg/m2 | Oral |
| Subject | MK-0752 | Small molecule | 1400 mg/m2 | Oral |
| Subject | MK-0752 | Small molecule | 1800 mg/m2 | Oral |